September 26, 2017
August 25, 2017
July 24, 2017
June 14, 2017
May 10, 2017
April 21, 2017
June 27, 2016
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]